The limitations of current research are also noted, for instance, while certain YAP inhibitors demonstrate promise in preclinical models of specific tumors, there is a notable lack of clinical evidence regarding their efficacy and safety in cancer treatment. The gene discussed is YAP1; the disease is cancer.